

# ASX ANNOUNCEMENT

ASX Market Announcements  
Australian Securities Exchange Limited  
10<sup>th</sup> Floor, 20 Bond Street  
SYDNEY NSW 2000

## Admedus Limited (ASX:AHZ)

### ADMEDUS TAVR PROJECT PASSES TESTING MILESTONE

Admedus Limited (ASX:AHZ) today announced that its Transcatheter Aortic Valve Replacement (TAVR) device project passed a key developmental milestone by achieving the durability benchmark of 200 million cycle tests as required by the standard (ISO 5840-2:2015) for cardiovascular implants - "Cardiac valve prostheses Part 2: Surgically implanted heart valve substitutes".

This follows the announcement in October 2017, that Admedus submitted two separate IP applications in the United States for the development and manufacture of a three-dimensional replacement heart valve using Admedus' clinically superior proprietary ADAPT technology that requires minimal suturing; and a hydro-packaging system to revolutionise the way TAVR products are assembled and distributed.

Since lodging the IP applications, Admedus has actively continued the research and development phase of the project which potentially offers a long-term opportunity to enter the global TAVR market that is currently worth an estimated \$US3B and projected to reach \$US5B by 2020.

CEO Wayne Paterson said,

"As previously announced, Admedus is investing in the development of a clinically-superior product that offers the substantial health benefits of our ADAPT technology and an alternative treatment option for patients who aren't suitable candidates for traditional surgical heart valve replacement or repair."

"Passing the 200 million valve cycle test is a critical step in this pre-clinical stage of development as it confirms the valve meets the required standard of durability - fundamental to the overall viability and progression of the project."

"There's still a lot of work to be done in the development and testing phases but successfully completing the cycle durability test gives us the green light to continue our investment in this strategically important initiative."

"If successful, the Admedus TAVR will reinvent the way these devices are used and manufactured."

**Admedus Limited**  
ABN 35 088 221 078

**Registered Office**  
Level 9  
301 Coronation Drive  
Milton QLD 4064

**Customer Service**  
T 1300 550 310  
F 1300 880 398

**International**  
T: +61 8 9266 0100  
F: +61 8 9266 0199

E: [info@admedus.com](mailto:info@admedus.com)  
W: [www.admedus.com](http://www.admedus.com)

**Brisbane • Minneapolis**  
**Zurich • Singapore**



“By leveraging the latest advances in our ADAPT tissue technology to create a three-dimensional, single-piece moulded valve which securely attaches to a stent with minimal sutures, we anticipate a substantial reduction in the cost of manufacturing a TAVR device.”

“We believe that the combination of our clinically-superior ADAPT treated tissue, three-leaflet, single-piece valve design and patented hydro-packaging, has the potential to deliver the most unique, high-quality and cost-effective TAVR product on the market.”

ADAPT inventor and VP Cardiovascular Technologies Professor Leon Neethling added,

“The benefits of our proprietary ADAPT technology and products are now confirmed with more than nine years of data to demonstrate their remodelling and anti-calcification properties.”

“Our team is excited by the potential of Admedus’ TAVR device and the opportunity to share the health benefits of ADAPT treated tissue across an expanded range of clinical applications.”

“We recently held a productive clinical Advisory Board meeting with a number of leading US experts in the TAVR and cardiovascular space which delivered valuable feedback and we look forward to further collaboration as the project progresses.”

**ENDS**

## **Background:**

### **ADAPT®**

ADAPT® treated tissue has been scientifically proven to more closely mimic the characteristics of normal human tissue which promotes a more tolerant immune response and improved tissue ingrowth. Our clinically superior ADAPT® tissue products are the only one of their kind to have achieved nine years without calcification or degradation. With the potential for a product lifespan free from calcification, physicians can potentially intervene across a broader age spectrum and provide their patients with a solution for life.

### **About Admedus Limited**

Admedus (ASX:AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

**Admedus Limited**  
ABN 35 088 221 078

**Registered Office**  
Level 9  
301 Coronation Drive  
Milton QLD 4064

**Customer Service**  
T 1300 550 310  
F 1300 880 398

**International**  
T: +61 8 9266 0100  
F: +61 8 9266 0199

E: [info@admedus.com](mailto:info@admedus.com)  
W: [www.admedus.com](http://www.admedus.com)

**Brisbane • Minneapolis**  
**Zurich • Singapore**



Website: [www.admedus.com](http://www.admedus.com)  
Facebook: [www.facebook.com/Admedus](http://www.facebook.com/Admedus)  
Twitter: @Admedus

*For more information, please contact:*

Admedus Limited  
Barbara Ferres  
+61 7 3152 3216  
[communications@admedus.com](mailto:communications@admedus.com)

**Admedus Limited**  
ABN 35 088 221 078

**Registered Office**  
Level 9  
301 Coronation Drive  
Milton QLD 4064

**Customer Service**  
T 1300 550 310  
F 1300 880 398

**International**  
T: +61 8 9266 0100  
F: +61 8 9266 0199

E: [info@admedus.com](mailto:info@admedus.com)  
W: [www.admedus.com](http://www.admedus.com)

**Brisbane • Minneapolis**  
**Zurich • Singapore**